These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 32127527

  • 1. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.
    Yadav P, Sathick IJ, Leung N, Brown EE, Cook M, Sanders PW, Cockwell P.
    Blood Cancer J; 2020 Mar 03; 10(3):28. PubMed ID: 32127527
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.
    Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon JM, Fermand JP, Touchard G, Bridoux F.
    Nephrol Dial Transplant; 2016 Jan 03; 31(1):64-72. PubMed ID: 26289418
    [Abstract] [Full Text] [Related]

  • 3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.
    Nephrol Dial Transplant; 2012 Oct 03; 27(10):3823-8. PubMed ID: 22273664
    [Abstract] [Full Text] [Related]

  • 4. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
    Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N.
    J Am Soc Nephrol; 2011 Jun 03; 22(6):1129-36. PubMed ID: 21511832
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F, Chaintreuil D, Jolivot A, Guebre-Egziabher F, Robinson P, Karlin L, Bridoux F, Juillard L.
    Am J Nephrol; 2017 Jun 03; 46(5):355-363. PubMed ID: 29017155
    [Abstract] [Full Text] [Related]

  • 6. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
    Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS, Cairns D, Owen RG, Davies FE, Jackson GH, Child JA, Morgan GJ, Drayson MT.
    BMC Nephrol; 2018 Jul 13; 19(1):178. PubMed ID: 30012107
    [Abstract] [Full Text] [Related]

  • 7. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.
    Nefrologia; 2013 Jul 13; 33(4):515-23. PubMed ID: 23897183
    [Abstract] [Full Text] [Related]

  • 8. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
    Decourt A, Gondouin B, Delaroziere JC, Brunet P, Sallée M, Burtey S, Dussol B, Ivanov V, Costello R, Couchoud C, Jourde-Chiche N.
    Clin J Am Soc Nephrol; 2016 Mar 07; 11(3):431-41. PubMed ID: 26728585
    [Abstract] [Full Text] [Related]

  • 9. Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.
    Manohar S, Nasr SH, Leung N.
    Curr Hematol Malig Rep; 2018 Jun 07; 13(3):220-226. PubMed ID: 29725932
    [Abstract] [Full Text] [Related]

  • 10. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G.
    BMC Nephrol; 2008 Sep 22; 9():11. PubMed ID: 18808676
    [Abstract] [Full Text] [Related]

  • 11. Management options for cast nephropathy in multiple myeloma.
    Cockwell P, Hutchison CA.
    Curr Opin Nephrol Hypertens; 2010 Nov 22; 19(6):550-5. PubMed ID: 20827195
    [Abstract] [Full Text] [Related]

  • 12. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
    Granger Vallée A, Chenine L, Leray-Moragues H, Patrier L, Cognot C, Cartron G, Cristol JP, Canaud B.
    Nephrol Dial Transplant; 2011 Nov 22; 26(11):3627-33. PubMed ID: 21508098
    [Abstract] [Full Text] [Related]

  • 13. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR.
    J Am Soc Nephrol; 2007 Mar 22; 18(3):886-95. PubMed ID: 17229909
    [Abstract] [Full Text] [Related]

  • 14. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
    Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M.
    Lancet Haematol; 2019 Apr 22; 6(4):e217-e228. PubMed ID: 30872075
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y.
    Ther Apher Dial; 2010 Oct 22; 14(5):451-6. PubMed ID: 21175542
    [Abstract] [Full Text] [Related]

  • 16. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both.
    Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N.
    Leuk Lymphoma; 2015 Oct 22; 56(12):3357-64. PubMed ID: 25860232
    [Abstract] [Full Text] [Related]

  • 17. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
    Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL.
    Kidney Int; 2008 Jun 22; 73(11):1282-8. PubMed ID: 18385667
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.
    Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P.
    Clin J Am Soc Nephrol; 2009 Apr 22; 4(4):745-54. PubMed ID: 19339414
    [Abstract] [Full Text] [Related]

  • 20. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
    Yadav P, Hutchison CA, Basnayake K, Stringer S, Jesky M, Fifer L, Snell K, Pinney J, Drayson MT, Cook M, Cockwell P.
    Eur J Haematol; 2016 Jun 22; 96(6):610-7. PubMed ID: 26248588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.